Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3817MR)

This product GTTS-WQ3817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7108MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ7693MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4612MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ8618MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ15780MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ4035MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ5536MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ5156MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW